Sarah Jessica Parker Has An Important Reason To Speak Out Against The EpiPen Price Hike

"I'm left disappointed, saddened and deeply concerned."

The news that pharmaceutical company Mylan is raising the price of the EpiPen has caused outrage and worry that individuals with life-threatening allergies will not be able to afford the shot. A two-pack of pens, which was $100 in 2009, will now cost as much as $600. The product's one-year expiration date adds to the concern.

Actress Sarah Jessica Parker, whose son has a serious peanut allergy, had partnered with Mylan for the Anaphylaxis For Reel campaign earlier this year to raise awareness for anaphylaxis, which affects 1 in 50 Americans.


In light of the recent price hike, Parker announced on Instagram Thursday that she is cutting ties with Mylan, saying she is "disappointed, saddened and deeply concerned" by the company's actions, which "renders the medicine cost-prohibitive for countless people."

She shared her own personal experience and understanding of the EpiPen's importance to so many people's health, writing, "The Epinephrine Auto-Injector is a vital part of our family's healthcare, as it is for the many who are at risk."

She continued, "I hope they will seriously consider the outpouring of voices of those millions of people who are dependent on the device, and take swift action to lower the cost to be more affordable for whom it is a life-saving necessity."

Parker and her son James Wilkie

Meanwhile, Mylan announced this week that it would offer savings cards to lessen the cost and expand eligibility for patients to receive financial assistance. However, many people disappointed in the company's decision say this is not enough. 

Sen. Richard Blumenthal of Connecticut, for instance, called it "a PR fix more than a real remedy" and added, "What's needed is robust, real action to lower the price for everyone, not just a select few."

Cover image via Instagram

(H/T: Huffington Post)


Subscribe to our newsletter and get the latest news and exclusive updates.